Favorites Sign in

One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
  1. Home
  2. Companies
  3. Veeva Systems
  4. Financial Ratios
Veeva Systems logo
Veeva Systems VEEV
$ 320.55 0.59%
report update icon

Quarterly report 2027-Q2
added 08-27-2026

Veeva Systems Financial Ratios 2026-2011 | VEEV

Brief overview of Veeva Systems 's market valuation

The review covers five available annual periods spanning 2022 to 2026.

The valuation comparison uses P/E 33.15x (median 56.6x), EV/EBITDA 32.75x (median 52.67x), P/S 9.43x (median 12.81x). Valuation is roughly 39.8% below five-year reference levels. The discount may reflect opportunity or higher perceived risk.

Current earnings relative to valuation equal about 3% on the 1/P/E measure. This is a valuation reference, not an expected payout.

Returns on assets and capital are represented by ROE 12.6%, ROA 10.1%, ROCE 12.7%. Profitability remains positive and sufficient for normal operations without indicating exceptional efficiency.

PEG is 1.63x. Price is well ahead of embedded growth, making market expectations demanding.

The cash conversion cycle lengthened from 102.1 days to 114.1 days, or 12 days. More cash is tied up in operations.

Overall picture

Veeva Systems 's fundamental efficiency looks stronger than its current valuation relative to history. Future reports should confirm the conclusion.

Annual Financial Ratios Veeva Systems

2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

P/E

 33.1 41.7 70.1 56.6 63.7 101.3 69.7 75.5 72.9 86.8 60.8 98.0 77.3 - - -

P/S

 9.4 10.8 15.6 12.8 14.7 26.3 19.0 20.1 15.1 11.0 8.1 12.6 8.7 - - -

EPS

 5.5 4.4 3.3 3.1 2.8 2.5 2.0 1.6 1.1 0.6 0.4 0.3 0.2 0.2 0.0 -

EV (Enterprise Value)

 30.5 B 30.2 B 37.4 B 27.8 B 27 B 38.5 B 21.1 B 17.2 B 10.4 B 6.02 B 3.38 B 3.97 B 1.65 B 24 M 10.4 M -

EBITDA per Share

 5.68 4.39 2.71 2.99 3.34 2.57 2.07 1.64 1.18 0.898 0.659 0.579 0.806 - - -

EV/EBITDA

 32.7 42.5 85.9 59.8 52.7 99.5 67.0 70.9 60.8 47.2 36.5 51.8 37.5 - - -

PEG

 1.63 2.17 5.81 2.59 2.11 3.23 2.46 1.31 0.74 3.56 1.88 3.36 1.88 - - -

P/B

 4.2 5.1 7.9 7.4 9.4 17.0 12.6 14.0 11.9 9.1 6.6 9.7 6.5 - - -

P/CF

 21.3 27.3 40.4 35.4 35.6 69.8 48.5 57.6 46.6 43.7 57.1 97.4 47.1 - - -

ROE %

 12.60 12.24 11.32 13.12 14.68 16.77 18.08 18.57 16.29 10.54 10.78 9.93 8.43 - - -

ROA %

 10.12 9.73 8.89 10.15 11.20 12.48 13.25 13.90 11.86 7.50 7.72 7.41 6.38 - - -

ROCE %

 12.70 11.86 9.24 12.35 17.36 16.67 16.63 17.79 17.09 16.09 15.13 17.09 13.85 - - -

Current Ratio

 5.1 4.9 4.7 4.4 4.2 3.9 2.8 3.6 3.2 2.9 2.7 3.7 4.1 - - -

DSO

 130.0 124.2 120.1 113.0 117.9 118.8 139.7 136.1 124.4 122.7 129.2 108.0 103.9 - - -

DPO

 15.9 16.2 19.7 18.6 15.8 19.0 23.4 13.6 12.0 11.9 11.8 12.3 9.4 - - -

Operating Cycle

 130.0 124.2 120.1 113.0 117.9 118.8 139.7 136.1 124.4 122.7 129.2 108.0 103.9 - - -

Cash Conversion Cycle

 114.1 108.0 100.4 94.4 102.1 99.8 116.3 122.6 112.5 110.7 117.3 95.7 94.5 - - -

All numbers in USD currency

Quarterly Financial Ratios Veeva Systems

2027-Q2 2027-Q1 2026-Q4 2026-Q3 2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

EPS

 1.23 1.6 - 1.44 1.23 1.4 - 1.44 1.23 1.4 - 1.15 1.06 1 - 0.84 0.7 0.82 - 0.7 0.58 0.65 0.68 0.69 0.71 0.76 0.44 0.64 0.62 0.58 0.49 0.56 0.54 0.5 0.29 0.44 0.35 0.31 0.16 0.25 0.28 0.27 0.13 0.16 0.1 0.09 0.1 0.08 0.1 0.1 0.05 0.08 0.07 0.06 - 0.07 0.05 0.04 - 0.05 - - - - - -

EBITDA per Share

 1.22 1.69 - 1.49 1.22 1.46 - 1.49 1.22 1.46 - 1.15 1.06 0.99 - 0.83 0.65 0.39 - 0.79 0.67 0.84 - 0.88 0.83 0.86 - 0.68 0.61 0.6 - 0.58 0.54 0.52 - 0.46 0.39 0.33 - 0.33 0.3 0.31 - 0.27 0.2 0.16 0.16 0.17 0.18 0.17 0.09 0.16 0.14 0.11 0.38 0.3 0.42 0.39 - 0.43 - - - - - -

ROE %

 13.38 13.62 10.05 13.40 13.06 13.72 10.05 13.42 13.37 13.66 9.98 13.07 12.38 12.42 9.11 12.28 11.99 12.56 9.23 13.77 14.42 15.78 17.25 16.68 17.46 18.08 18.16 19.94 20.61 21.32 22.01 20.75 21.10 20.40 19.45 18.17 16.80 17.05 17.72 17.89 17.19 14.45 11.59 11.50 10.14 10.80 11.47 10.42 10.90 10.63 9.79 24.29 24.01 2.19 16.73 2.41 - - - - - - - - - -

ROA %

 10.51 11.22 8.36 11.28 10.86 11.30 8.36 11.24 10.91 10.54 7.60 10.22 7.34 7.34 7.34 9.93 9.55 9.91 7.29 10.67 11.22 12.27 13.36 12.89 13.50 13.97 13.98 15.37 15.95 16.49 17.03 16.03 16.29 15.71 14.94 14.00 12.75 12.79 13.15 13.27 12.68 10.60 8.55 8.50 7.43 8.05 8.67 7.91 8.32 8.12 7.49 12.13 11.94 1.66 6.33 1.89 - - - - - - - - - -

ROCE %

 13.47 13.87 10.14 13.56 13.09 13.90 10.14 13.43 13.22 13.44 9.68 12.61 11.82 10.17 7.00 10.55 10.73 12.39 10.83 15.19 16.43 18.07 19.16 18.43 18.45 18.29 17.90 19.36 19.74 20.25 20.72 19.87 20.23 20.15 19.33 19.88 19.53 19.47 20.44 18.55 18.94 18.19 16.07 18.24 16.90 17.61 19.13 18.08 19.07 18.84 17.77 41.29 39.75 3.80 27.56 3.69 - - - - - - - - - -

Current Ratio

 5.1 5.0 4.9 7.7 5.9 5.0 4.7 7.7 5.9 5.0 4.4 6.8 - - 4.2 6.2 4.9 4.7 4.2 5.5 4.7 4.2 3.9 5.6 4.6 4.2 3.8 5.4 4.5 4.0 4.0 5.6 4.5 4.0 3.8 5.4 4.3 3.8 3.5 4.6 3.9 3.5 3.5 4.3 3.5 3.4 4.0 4.1 4.3 4.1 4.1 4.4 4.3 4.2 1.6 4.6 - - - - - - - - - -

DSO

 105.7 81.9 - 41.4 52.9 80.8 - 41.4 52.9 71.9 - 16.7 - 44.3 - 47.0 61.2 90.5 - 45.9 54.9 80.8 89.2 47.4 54.7 68.6 83.9 48.9 58.9 73.0 82.5 42.6 52.9 72.5 77.2 41.0 58.0 78.8 78.7 44.7 57.2 73.7 84.0 49.4 59.3 66.5 88.1 61.1 64.3 65.3 75.3 58.3 74.2 67.2 98.3 40.3 - - - - - - - - - -

DPO

 18.3 14.7 - 15.2 16.6 18.1 - 15.2 16.6 20.8 - 8.3 - 5.3 - 23.4 25.5 17.7 - 21.3 16.9 15.9 - 16.5 15.0 15.0 - 16.7 14.8 11.6 - 11.5 11.0 10.7 - 13.8 12.8 11.2 - 11.8 10.4 9.1 - 11.9 11.9 9.5 16.2 13.7 12.5 10.6 8.0 5.9 7.9 11.3 15.7 5.2 - - - - - - - - - -

Operating Cycle

 - - - - - - - 41.4 52.9 45.0 - - - - - 47.0 61.2 90.5 - 45.9 54.9 80.8 89.2 47.4 54.7 68.6 83.9 48.9 58.9 73.0 82.5 42.6 52.9 72.5 77.2 41.0 58.0 78.8 78.7 44.7 57.2 73.7 84.0 49.4 59.3 66.5 88.1 61.1 64.3 65.3 75.3 58.3 74.2 67.2 98.3 40.3 - - - - - - - - - -

Cash Conversion Cycle

 - - - - - - - 26.3 36.3 26.8 - - - - - 23.5 35.8 72.8 - 24.6 38.0 64.8 89.2 30.9 39.7 53.6 83.9 32.1 44.1 61.4 82.5 31.1 41.9 61.8 77.2 27.2 45.2 67.6 78.7 32.9 46.8 64.5 84.0 37.5 47.4 57.0 71.8 47.5 51.8 54.7 67.3 52.4 66.3 55.9 82.5 35.1 - - - - - - - - - -

All numbers in USD currency

Multiples are an important financial analysis tool for the company Veeva Systems , allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Health information services industry

Issuer Price % 24h Market Cap Country
American Well Corporation American Well Corporation
AMWL
 		$ 13.97 5.91 % $ 224 M usaUSA
Evolent Health Evolent Health
EVH
 		$ 4.83 -0.82 % $ 552 M usaUSA
NextGen Healthcare NextGen Healthcare
NXGN
 		- - $ 1.6 B usaUSA
Covetrus Covetrus
CVET
 		- - $ 2.94 B usaUSA
1Life Healthcare 1Life Healthcare
ONEM
 		- - $ 3.37 B usaUSA
R1 RCM R1 RCM
RCM
 		- - $ 3.81 B usaUSA
Change Healthcare Change Healthcare
CHNG
 		- - $ 9.03 B usaUSA
Signify Health Signify Health
SGFY
 		- -0.02 % $ 7.21 B usaUSA
Tabula Rasa HealthCare Tabula Rasa HealthCare
TRHC
 		- - $ 255 M usaUSA
Cerner Corporation Cerner Corporation
CERN
 		- - $ 27.9 B usaUSA
iCAD iCAD
ICAD
 		- - $ 102 M usaUSA
Accolade Accolade
ACCD
 		- 0.29 % $ 206 M usaUSA
Allscripts Healthcare Solutions Allscripts Healthcare Solutions
MDRX
 		- -10.39 % $ 886 M usaUSA
NantHealth NantHealth
NH
 		- -46.64 % $ 10.4 M usaUSA
Omnicell Omnicell
OMCL
 		$ 36.34 -0.41 % $ 1.67 B usaUSA
OptimizeRx Corporation OptimizeRx Corporation
OPRX
 		$ 9.37 4.93 % $ 174 M usaUSA
Phreesia Phreesia
PHR
 		$ 12.26 1.78 % $ 732 M usaUSA
GoodRx Holdings GoodRx Holdings
GDRX
 		$ 3.57 1.42 % $ 1.27 B usaUSA
Health Catalyst Health Catalyst
HCAT
 		$ 1.74 -0.57 % $ 122 M usaUSA
So-Young International So-Young International
SY
 		$ 2.19 -3.1 % $ 171 M chinaChina
Teladoc Health Teladoc Health
TDOC
 		$ 6.3 1.45 % $ 1.11 B usaUSA
HealthEquity HealthEquity
HQY
 		$ 97.88 1.33 % $ 8.43 B usaUSA
Schrödinger Schrödinger
SDGR
 		$ 23.9 2.14 % $ 1.76 B usaUSA
Zhongchao Zhongchao
ZCMD
 		$ 1.34 -4.96 % $ 4.58 M chinaChina
Castlight Health, Inc. Castlight Health, Inc.
CSLT
 		- -7.28 % $ 227 M usaUSA
HMS Holdings Corp. HMS Holdings Corp.
HMSY
 		- - $ 3.29 B usaUSA
Inovalon Holdings, Inc. Inovalon Holdings, Inc.
INOV
 		- - $ 6.37 B usaUSA
HealthStream HealthStream
HSTM
 		$ 33.51 -0.77 % $ 1.01 B usaUSA
Progyny Progyny
PGNY
 		$ 28.44 -0.49 % $ 2.42 B usaUSA
10x Genomics 10x Genomics
TXG
 		$ 75.59 5.78 % $ 9.43 B usaUSA
Computer Programs and Systems Computer Programs and Systems
CPSI
 		- 4.4 % $ 133 M usaUSA
Akerna Corp. Akerna Corp.
KERN
 		- - $ 161 M usaUSA
MTBC MTBC
MTBC
 		- -0.58 % $ 51.7 M usaUSA
Premier Premier
PINC
 		- - $ 2.33 B usaUSA
Streamline Health Solutions Streamline Health Solutions
STRM
 		- - $ 21.4 M usaUSA
SCWorx Corp. SCWorx Corp.
WORX
 		- - $ 7.71 M usaUSA